BKD vs. TARS, DCPH, ABCL, OMCL, SLNO, AKRO, COLL, OCUL, XNCR, and KNSA
Should you be buying Brookdale Senior Living stock or one of its competitors? The main competitors of Brookdale Senior Living include Tarsus Pharmaceuticals (TARS), Deciphera Pharmaceuticals (DCPH), AbCellera Biologics (ABCL), Omnicell (OMCL), Soleno Therapeutics (SLNO), Akero Therapeutics (AKRO), Collegium Pharmaceutical (COLL), Ocular Therapeutix (OCUL), Xencor (XNCR), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "medical" sector.
Brookdale Senior Living (NYSE:BKD) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.
Brookdale Senior Living received 424 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 67.00% of users gave Brookdale Senior Living an outperform vote while only 62.90% of users gave Tarsus Pharmaceuticals an outperform vote.
Brookdale Senior Living has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
Tarsus Pharmaceuticals has lower revenue, but higher earnings than Brookdale Senior Living. Brookdale Senior Living is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Tarsus Pharmaceuticals has a net margin of 0.00% compared to Brookdale Senior Living's net margin of -6.27%. Brookdale Senior Living's return on equity of -44.01% beat Tarsus Pharmaceuticals' return on equity.
Brookdale Senior Living presently has a consensus price target of $7.50, suggesting a potential upside of 7.76%. Tarsus Pharmaceuticals has a consensus price target of $48.38, suggesting a potential upside of 50.98%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Brookdale Senior Living.
In the previous week, Brookdale Senior Living and Brookdale Senior Living both had 5 articles in the media. Brookdale Senior Living's average media sentiment score of 1.14 beat Tarsus Pharmaceuticals' score of 0.52 indicating that Brookdale Senior Living is being referred to more favorably in the media.
90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 1.5% of Brookdale Senior Living shares are owned by company insiders. Comparatively, 11.5% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Tarsus Pharmaceuticals beats Brookdale Senior Living on 9 of the 17 factors compared between the two stocks.
Get Brookdale Senior Living News Delivered to You Automatically
Sign up to receive the latest news and ratings for BKD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brookdale Senior Living Competitors List
Related Companies and Tools
